Shares of Strongbridge Biopharma plc (NASDAQ:SBBP) climbed 58 percent Wednesday to close at $6.40 as Novo Nordisk A/S agreed to pay $145 million plus royalties for U.S. and Canadian rights to the adult growth hormone deficiency therapy (AGHD) Macrilen (macimorelin), rights that Strongbridge itself had purchased less than a year ago from Aeterna Zentaris Inc. for $24 million up front. Novo also made an equity investment in the company.